Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain

被引:13
作者
Muñoz, M
Carmona, R
Pérez-Alvarez, L
Cilla, G
Suarez, MD
Delgado, E
Contreras, G
Corral, J
de Goicoetxea, MJL
Medrano, L
Lezaún, MJ
Nájera, R
机构
[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Viral Pathogenesis Dept, Madrid 28220, Spain
[2] Complejo Hosp Donosstia, Guipuzcoa, Basque Country, Spain
[3] Hosp Basurto, Vizcaya, Basque Country, Spain
[4] Hosp Cruces, Vizcaya, Basque Country, Spain
[5] Hosp Galdakao, Vizcaya, Basque Country, Spain
[6] Hosp Txagorritsu, Alava, Basque Country, Spain
关键词
HIV-1; resistance; antiretrovirals; discrepancies; genotypic analysis; phenotypic analysis;
D O I
10.1016/j.jcv.2004.06.014
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Genotypic and phenotypic analysis of HIV-1 resistance mutations constitute one important point for providing guidelines in the choice of antiretroviral regimens and to design lines of rescue treatment for patients holding HIV-1 drug-resistant variants. However, some levels of discordance among them has been described. Objectives: (i) To compare the genotypic analysis of resistance mutations to reverse transcriptase (RT) and protease (PR) inhibitors by Stanford HIVdb program (http:/hivdb.stanford.edu) (St-HIVdb), and genotype with quantitative phenotypic analysis (Virtual Phenotype (TM), VircoNET). (ii) To identify drug resistance mutations associated with discrepant results. Study design: Five hundred HIV-1 infected patients were included in this study. RNA was extracted from plasma. RT and PR regions were amplified and sequenced using ABI-Prism DNA sequencing system. Sequences were corrected and assembled with Seqman and Bioedit computer programs. The corrected sequences were submitted to the Stanford HIV-Seq program (http:/hivdb.stanford.edu) and to Virtual Phenotype (TM) (VircoNET). Results: Discrepant cases were considered if results were high or intermediate resistant by Stanford HIV-Seq program and susceptible by Virtual Phenotype (TM), being detected as follows: (i) nucleoside RT inhibitors (NRT): 31.7% (ABC) 31% (d4T), 29.5% (ddC), 27.6% (ddI), 14.3% (TDF) and 11.3% (ZDV) and to PR inhibitors: 8.8% (SQV), 5% (APV), 3.8% (NFV) and 3.2% (IDV). These discrepant results were related to the presence of thymidine analogue mutations (TAMs) and also to key resistance mutations to NRT inhibitors: 65R, 69D/N, 74V/I, 184V/I and 215Y/F. (ii) PR inhibitors: 82A/F/T/S, 84I and 90M. Concordant results were considered when the interpretations by both programs were coincident, being higher than 96.7% for non-NRT inhibitors. Conclusions: The detection of discrepant results to NRT inhibitors and PR inhibitors, including the analysis of sequences with key resistant mutations to some drugs, means that further investigation is necessary in order to establish which is the best interpretation system as antiretroviral therapy guide. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 20 条
[1]   Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing [J].
De Luca, A ;
Perno, CF .
CURRENT OPINION IN INFECTIOUS DISEASES, 2003, 16 (06) :573-580
[2]   Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations [J].
Demeter, L ;
Haubrich, R .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 :S3-S9
[3]   Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs [J].
Dunne, AL ;
Mitchell, FM ;
Coberly, SK ;
Hellmann, NS ;
Hoy, J ;
Mijch, A ;
Petropoulos, CJ ;
Mills, J ;
Crowe, SM .
AIDS, 2001, 15 (12) :1471-1475
[4]  
*EUR AIDS CLIN SOC, 2003, AIDS S2, V17, pS3
[5]   Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
Clotet, B ;
Conway, B ;
Kuritzkes, DR ;
D'Aquila, RT ;
Demeter, LM ;
Hammer, SM ;
Johnson, VA ;
Loveday, C ;
Mellors, JW ;
Jacobsen, DM ;
Richman, DD .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128
[6]  
KIJAK GH, 2003, HIV MED, V4, P75
[7]   Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure:: a randomized trial [J].
Meynard, JL ;
Vray, M ;
Morand-Joubert, L ;
Race, E ;
Descamps, D ;
Peytavin, G ;
Matheron, S ;
Lamotte, C ;
Guiramand, S ;
Costagliola, D ;
Brun-Vézinet, F ;
Clavel, F ;
Girard, PM .
AIDS, 2002, 16 (05) :727-736
[8]   Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance [J].
Parkin, NT ;
Chappey, C ;
Petropoulos, CJ .
AIDS, 2003, 17 (07) :955-961
[9]  
PEREZALVAREZ L, 2003, HIV MED, V4, P23
[10]  
Puchhammer-Stockl E, 2002, HIV Med, V3, P200, DOI 10.1046/j.1468-1293.2002.00116.x